No Data
Kunbo Medical-B (02216.HK): The lung imaging processing software BRONCQCT has been approved for launch in China.
On March 21, according to Gelonghui, Kunbo Medical-B (02216.HK) announced that its lung imaging processing Software BroncQCT (hereinafter referred to as "the Software") has officially been approved by the Zhejiang Provincial Pharmaceutical Administration for launch in China. The approval for this Software reflects the group's commitment to developing solutions that enhance clinical benefits, further solidifying the company's position in the field of precise intervention diagnosis and treatment of lung diseases. The Software is expected to improve doctors' efficiency in interpreting lung Computed Tomography (CT) images, providing strong support for clinical auxiliary diagnosis and treatment, and promoting a more efficient and precise diagnostic process.
Kunbo Medical-B (02216.HK) will hold a Board of Directors meeting on March 31 to approve the annual performance.
Gelonghui, March 19丨Kunbo Medical-B (02216.HK) announced that the Board of Directors will hold a meeting on March 31, 2025, to approve (including) the annual results of the company and its subsidiaries for the year ending December 31, 2024, and to propose the distribution of a final dividend (if any).
BRONCUS-B: DATE OF BOARD MEETING
Kunbo Medical-B (02216.HK) spent 0.117 million HKD to repurchase 0.15 million shares on February 27.
According to Gelonghui on February 27, Kunbo Medical-B (02216.HK) announced that on February 27, 2025, it spent 0.117 million HKD to repurchase 0.15 million shares, with a repurchase price of 0.77-0.79 HKD per share.
The new drug development time is cut in half, diagnoses are more accurate, industry barriers are lowered... AI is transforming the Medical Industry in China.
On February 26, Deutsche Bank Analyst Cyrus Ng released a report stating that the entire Medical Industry in China, from drug development and diagnostics to Hospital management, will benefit from the AI revolution.
The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus
① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.
102768097 : how to do?